Pharmaceutical company Biocad has become a partner of the state scientific center of Virology and biotechnology “Vector” on the development of a vaccine against COVID-19. This organization is subordinate to the CPS, which had previously received from the government of the Russian Federation RUB 1.5 billion for the development of prevention and diagnosis of novel coronavirus infection.Biocad and Vector have signed an agreement to work together on a vaccine against COVID-19, by the centre. As the message of the pharmaceutical companies, the vaccine showed promise in tests on laboratory animals, and now we are always willing to take on the costs of clinical research and the organization of production. The volume of investments is not disclosed.After that Supplies will be ready to provide your own power for the industrial production of vaccines, adds CEO Dmitry Morozov.In parallel, Biocad is developing its own vaccine against the coronavirus. In late March the company agreed in the MoH terms and programs of preclinical and first-phase clinical development of vaccines. The beginning of clinical trials is expected to be no more than five months.Biocad, one of Russia’s largest pharmaceutical company, manufactures drugs for treatment of oncological, autoimmune, infectious and other socially significant diseases. CJSC “Biocad” is 100% owned by the Cypriot Biocad Holding, in which 20% of “Pharmstandard” Victor Haritonin and 50% of his teammate Valeriya Egorova, 30% — at the General Director of the company Dmitry Morozov. According to “SPARK-Interfax” revenue in 2018 reached 17.8 billion RUB compared to 12.5 billion RUB, net profit increased from RUB 3.8 bn to RUB 7.5 billion Earlier, the Russian government has allocated CPS 1.5 billion rubles for the development of diagnostic tools and prevention of novel coronavirus infection. Uniting the efforts of Biocad and “Vector” may be necessary in order to identify whose development is the most promising and work together to bring it to the final, believes the General Director DSM Group Sergey shuljak. In his opinion, the use of modern research center Biocad will reduce the timing of release of the vaccine.Maria Kotova
